134 related articles for article (PubMed ID: 25297732)
1. [Molecular basis of hematological malignancies].
Kitamura T; Inoue D; Nakahara F; Okochi N; Kato N; Togami K; Uchida T; Kagiyama Y; Kawabata KC; Nagase R; Horikawa S; Hayashi K; Saika M; Izawa K; Oki T; Chiba S; Harada Y; Harada H; Kitaura J
Rinsho Ketsueki; 2014 Oct; 55(10):1715-23. PubMed ID: 25297732
[No Abstract] [Full Text] [Related]
2. Landmark analysis of DNMT3A mutations in hematological malignancies.
Roller A; Grossmann V; Bacher U; Poetzinger F; Weissmann S; Nadarajah N; Boeck L; Kern W; Haferlach C; Schnittger S; Haferlach T; Kohlmann A
Leukemia; 2013 Jul; 27(7):1573-8. PubMed ID: 23519389
[No Abstract] [Full Text] [Related]
3. RNA methylation in hematological malignancies and its interactions with other epigenetic modifications.
Yao L; Yin H; Hong M; Wang Y; Yu T; Teng Y; Li T; Wu Q
Leukemia; 2021 May; 35(5):1243-1257. PubMed ID: 33767371
[TBL] [Abstract][Full Text] [Related]
4. Role of epigenetic changes in hematological malignancies.
Lehmann U; Brakensiek K; Kreipe H
Ann Hematol; 2004 Mar; 83(3):137-52. PubMed ID: 15064862
[TBL] [Abstract][Full Text] [Related]
5. [Epigenetics in hematological disorders].
Furukawa Y
Rinsho Ketsueki; 2008 Oct; 49(10):1472-82. PubMed ID: 18833931
[No Abstract] [Full Text] [Related]
6. Epigenetics in Cancer: A Hematological Perspective.
Stahl M; Kohrman N; Gore SD; Kim TK; Zeidan AM; Prebet T
PLoS Genet; 2016 Oct; 12(10):e1006193. PubMed ID: 27723796
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic dysregulation in hematological malignancies.
Iwama A
Int J Hematol; 2017 Jan; 105(1):5-6. PubMed ID: 27822916
[No Abstract] [Full Text] [Related]
8. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance.
Peller S; Rotter V
Hum Mutat; 2003 Mar; 21(3):277-84. PubMed ID: 12619113
[TBL] [Abstract][Full Text] [Related]
9. DNA methyltransferases in hematologic malignancies.
Li KK; Luo LF; Shen Y; Xu J; Chen Z; Chen SJ
Semin Hematol; 2013 Jan; 50(1):48-60. PubMed ID: 23507483
[TBL] [Abstract][Full Text] [Related]
10. GATA-2 L359 V mutation is exclusively associated with CML progression but not other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism.
Zhang SJ; Shi JY; Li JY
Leuk Res; 2009 Aug; 33(8):1141-3. PubMed ID: 19304323
[TBL] [Abstract][Full Text] [Related]
11. [Aberrant cytosine hydroxymethylation in hematologic malignancies].
Sakata-Yanagimoto M; Chiba S
Rinsho Ketsueki; 2013 May; 54(5):423-30. PubMed ID: 23727679
[No Abstract] [Full Text] [Related]
12. WNT5A is epigenetically silenced in hematologic malignancies and inhibits leukemia cell growth as a tumor suppressor.
Ying J; Li H; Chen YW; Srivastava G; Gao Z; Tao Q
Blood; 2007 Dec; 110(12):4130-2. PubMed ID: 18024799
[No Abstract] [Full Text] [Related]
13. The DNA methylation landscape of hematological malignancies: an update.
Blecua P; Martinez-Verbo L; Esteller M
Mol Oncol; 2020 Aug; 14(8):1616-1639. PubMed ID: 32526054
[TBL] [Abstract][Full Text] [Related]
14. EHA scientific workshop report: the role of epigenetics in hematological malignancies.
Jost E; Galm O
Epigenetics; 2007; 2(2):71-9. PubMed ID: 17965605
[TBL] [Abstract][Full Text] [Related]
15. High frequencies of simultaneous FLT3-ITD, WT1 and KIT mutations in hematological malignancies with NUP98-fusion genes.
Taketani T; Taki T; Nakamura T; Kobayashi Y; Ito E; Fukuda S; Yamaguchi S; Hayashi Y
Leukemia; 2010 Nov; 24(11):1975-7. PubMed ID: 20861915
[No Abstract] [Full Text] [Related]
16. [Epigenetics].
Tabe Y
Nihon Rinsho; 2012 Apr; 70 Suppl 2():86-90. PubMed ID: 23133933
[No Abstract] [Full Text] [Related]
17. Epigenetic inactivation of the miR-34a in hematological malignancies.
Chim CS; Wong KY; Qi Y; Loong F; Lam WL; Wong LG; Jin DY; Costello JF; Liang R
Carcinogenesis; 2010 Apr; 31(4):745-50. PubMed ID: 20118199
[TBL] [Abstract][Full Text] [Related]
18. The biology and clinical impact of genetic lesions in myeloid malignancies.
Lindsley RC; Ebert BL
Blood; 2013 Nov; 122(23):3741-8. PubMed ID: 23954890
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 1):1-10; quiz 11-2. PubMed ID: 21438190
[No Abstract] [Full Text] [Related]
20. [Epigenome in hematopoietic malignancies].
Iwama A
Rinsho Ketsueki; 2011 Oct; 52(10):1687-95. PubMed ID: 21971247
[No Abstract] [Full Text] [Related]
[Next] [New Search]
